Literature DB >> 12095879

Treatment of non-genital warts with topical imiquimod 5% cream.

Gianfranco Muzio1, Cesare Massone, Alfredo Rebora.   

Abstract

Common warts (verrucae vulgaris) are associated with human papillomavirus infection and are routinely treated by ablative procedures such as cryotherapy, electrodessiccation and salicylic acid. We report 10 cases of recurrent warts treated with a potential new topical therapy, imiquimod 5% cream. Nine of the 10 patients were successfully treated with imiquimod 5% cream applied, under occlusion, once daily for 4 weeks. No recurrences were reported during 3 months of follow up.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095879

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  5 in total

Review 1.  Skin conditions of baseball, cricket, and softball players.

Authors:  Joshua A Farhadian; Brook E Tlougan; Brian B Adams; Jonathan S Leventhal; Miguel R Sanchez
Journal:  Sports Med       Date:  2013-07       Impact factor: 11.136

2.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

3.  Topical adapalene in the treatment of plantar warts; randomized comparative open trial in comparison with cryo-therapy.

Authors:  Ramji Gupta; Sarthak Gupta
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

4.  A Novel Topical 2% Povidone-Iodine Solution for the Treatment of Common Warts: A Randomized, Double-Blind, Vehicle-Controlled Trial.

Authors:  Kara Capriotti; Kevin P Stewart; Jesse S Pelletier; Joseph Capriotti
Journal:  Dermatol Ther (Heidelb)       Date:  2015-11-03

5.  Immunotherapy with intralesional Candida albicans antigen in resistant or recurrent warts: a study.

Authors:  Imran Majid; Saher Imran
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.